Imigrane

Sumatriptan, the active ingredient in Imigrane, is a Triptan presented as a 20 mg nasal spray for nasal use. It treats acute migraine attacks in adults by targeting serotonin receptors to relieve headache pain and associated symptoms.

GNH USA supplies Imigrane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory adherence across markets. The company manages end‑to‑end logistics, documentation and post‑market support to meet the needs of healthcare providers globally, and our network includes certified distributors and quality‑assured storage facilities.

Sumatriptan is indicated for the acute treatment of migraine and related headache disorders. - Migraine: provides rapid relief of headache pain and associated symptoms during an acute attack. - Migraine with aura: alleviates headache and visual disturbances occurring with aura. - Cluster headache: can be used for the acute treatment of episodic cluster headache attacks.

Sumatriptan nasal spray may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Taste disturbance: altered or unpleasant taste after administration. - Nasal irritation: burning or stinging in the nasal passages. - Dizziness: sensation of light‑headedness or vertigo. - Nausea: mild stomach upset. Serious or Rare Side Effects: - Chest pain or tightness: possible cardiac ischemia symptoms. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity when combined with serotonergic agents. - Severe allergic reaction: rash, swelling, difficulty breathing.

When prescribing Sumatriptan nasal spray, clinicians should consider several precautionary measures to ensure patient safety. - Cardiovascular assessment: evaluate history of coronary artery disease or uncontrolled hypertension before use. - Concomitant serotonergic drugs: avoid co‑administration with MAO inhibitors or other triptans to reduce serotonin syndrome risk. - Hemiplegic or basilar migraine: contraindicated in patients with these migraine subtypes. - Pregnancy: use only if potential benefit justifies potential risk; category C. - Age limitation: not recommended for children under 12 years. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Sumatriptan may interact with other medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Other triptans or ergot derivatives: increased risk of vasospasm and cardiovascular events. - SSRIs/SNRIs: heightened potential for serotonin syndrome. Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase sumatriptan plasma levels. - Antihypertensive agents: additive blood pressure lowering effect. - Oral contraceptives: may slightly raise sumatriptan concentrations.